用于OUD的药物:延长释放的纳尔德.
1Division on Substance Use Disorders, Department of Psychiatry, Columbia University Irving Medical Center, New York, USA.
Current addiction reports
|March 9, 2026
概括
延长释放纳勒 (XR-NTX) 是一种有效的第一线治疗阿片类药物使用障碍 (OUD),与布普伦诺芬可比. 管理戒断并确保合规是减轻XR-NTX复发和过量使用风险的关键.
科学领域:
- 药理学 药理学是指药理学的学科.
- 成 药物 药物 药物 药物
- 公共卫生 公共卫生
背景情况:
- 阿片类药物使用障碍 (OUD) 是一种具有严重健康后果的慢性复发性疾病.
- 延长释放纳尔德 (XR-NTX) 是FDA批准的用于OUD治疗的药物.
- 证据支持XR-NTX的疗效及其在不同患者群体中的使用.
研究的目的:
- 审查支持OUD的XR-NTX的文献.
- 确定与XR-NTX治疗相关的局限性和挑战.
- 为OUD管理中XR-NTX提出未来研究方向.
主要方法:
- 随机对照试验和临床研究的文献综述.
- 在各种人群和物质使用障碍中分析XR-NTX疗效.
- 检查治疗启动和停止挑战.
主要成果:
- 在头对头试验中,XR-NTX的疗效与布普伦诺芬相当.
- XR-NTX在脆弱人群中有效,包括青少年,刑事司法罪犯和艾滋病毒感染患者.
- XR-NTX显示对酒精使用障碍的疗效,与布洛普一起,对甲基胺使用障碍的疗效.
结论:
- XR-NTX是OUD的第一线药物治疗选择,其有效性已被证明.
- 在诱导期间管理阿片类药物戒断对于成功启动XR-NTX至关重要.
- 在停止治疗后应对复发和过量服用等挑战对于患者的长期结果至关重要.
相关概念视频
Oral Drug Delivery Systems: Continuous-Release Systems
114
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
114
Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.3K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.3K
Opioid Receptors: Overview
5.7K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
5.7K
Modified-Release Drug Delivery Systems: Overview
82
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
82
Modified-Release Drug Delivery Systems: Drug Release Characteristics
91
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
91
Analgesia and Pain Management
2.6K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.6K


